Published on 2 Dec 2021 on Zacks via Yahoo Finance
Walgreens Boots Alliance, Inc. WBA has been reeling under the effects of persistent reimbursement pressure and a competitive market. The stock carries a Zacks Rank #4 (Sell).
Year to date, Walgreens Boots has underperformed the industry. The stock has gained 12.3% compared with the industry’s 27.1% rise. A shift in the mix of pharmacy prescription volume toward programs offering lower reimbursement rates might affect Walgreens Boots’ results of operations. The company’s 90-day retail offering for patients with chronic prescription needs typically is at a lower margin than comparable 30-day prescriptions.
In the last few years, a slowdown in generic introduction has been affecting Walgreens Boots’ margins. In addition, of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' margin significantly.
Start tracking your investments with StatfolioSign up for free